Shares of Exact Sciences Corp. (EXAS) traded over 2% higher on Tuesday afternoon after the company launched a new test ...

Summary: Myriad's Precise MRD test is an ultrasensitive second-generation hybrid-capture-based tumor-informed assay that ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive ...

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Corp announced the launch of Oncodetecta-a new test designed to detect molecular residual disease, MRD, across multiple ...

Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the ...

The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence ...

The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing.

This pivotal study aims to improve event-free survival rates and offers a timely treatment option using an investigational MRD test to identify high-risk individuals. Both trials reflect Allogene ...

Europe’s minimal residual disease (MRD) testing market has witnessed remarkable growth, underscoring its pivotal role in healthcare diagnostics. Valued at $265.6 million in 2021, this market is poised ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch ...